Xphyto Therapeutics Oral and Transdermal Cannabis Delivery and Dosage Systems

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2019) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to provide an update on the Company's thin film cannabis delivery and dosage systems in development by XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Vektor is a narcotics manufacturer, importer, and researcher located near Munich, Germany.

For over a decade, Vektor's founder and managing director, Professor Thomas Beckert, has been a leader in the development, testing and manufacture of thin film narcotics delivery systems, primarily transdermal patches and sublingual (oral) strips for the clinical management of pain. In addition to Vektor's expertise working with conventional pain narcotics such as Fentanyl, Hydromorphone, and Oxycodone, recent work has focused on the development of efficient cannabis delivery and dosage systems.

As the cannabis industry evolves, the opportunity to produce a well-defined dosage form has emerged as a major opportunity for XPhyto. High bioavailability with controlled, reproducible, and constant delivery is paramount. Results from initial studies using Vektor's formulation and oral delivery system for CBD have been extremely encouraging, demonstrating significant potential timing and efficiency advantages over other common oral methods (preliminary results in Figure 1 below). 

Figure 1. XPhyto results showing significantly improved dissolution properties of Vektor’s CBD formulations and oral delivery system vs softgel capsules and chewing gum.

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6452/49627_table1.jpg

Strong scientific data supporting XPhyto's non-inhalable cannabis delivery systems is significant in light of recent reports concerning e-cigarette and vape-related illnesses in North America. In the past 30 days, both the US Food & Drug Administration (FDA) and the US Centers for Disease Control & Prevention (CDC) have issued public statements warning consumers about lethal potential side effects that may be associated with e-cigarettes and vaping products. XPhyto and Vektor are prioritizing non-inhalable cannabis development programs for clinical advancement.

In addition to the global medical market, XPhyto is exploring near-term commercial opportunities for thin film consumer products in legal jurisdictions, including Canada.

About XPhyto Therapeutics Corp.

XPhyto is a next-generation cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). Bunker has two exclusive R&D collaboration agreements with the Technical University of Munich, Faculty of Chemistry as well as the Chair of Beverage and Brewing Technology. XPhyto acquired 100% of Vektor Pharma TF GmbH, a German narcotics manufacturer, importer and researcher with expertise in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain. XPhyto is pursuing additional opportunities in Germany including commercial cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.

For further information, please contact:

Hugh Rogers
CEO & Director
+1.780.818.6422
[email protected]
www.xphyto.com

Robert Barth
VP European Corporate Development
+49 8331 99481 10
[email protected]
www.xphyto.com

Forward looking statements

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building an industry leading medical cannabis company Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not derive the expected, or any, benefits from the Licence; that the Company may be unable to scale its business; product liability risks; frequent changes to cannabis regulations in Canada and internationally; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49627